Hikma releases info on DIFX

Hikma Pharmaceuticals Plc
10 May 2006




    Hikma publishes further information about the form and terms of its GDRs

LONDON, 10 May 2006 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, has today published further
information about the form and terms of its Global Depository Receipts (GDRs)
listed on the Dubai International Financial Exchange (DIFX).

This information can be found at 

www.difx.ae/market_information/hikma_informational_documents.html.

                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal                                                [phone]

Investor Relations Director

Brunswick Group

Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed    [phone]

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange